Altasciences, a fully integrated drug development solutions company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials.
This partnership combines Altasciences’ comprehensive early-stage drug development capabilities with VoxCell’s cutting-edge 3D tissue technology to create a more precise and human-relevant environment for preclinical testing. By integrating VoxCell’s high-resolution 3D bioprinting tissue platforms into Altasciences’ research and preclinical services, both companies aim to shorten research and development timelines and increase the success rate of investigational therapies.
“We are proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “This collaboration aligns with our commitment to the 3Rs and to innovative, efficient solutions that improve data quality and accelerate decision-making for our customers.”
Also Read: LucyRx Acquires CerpassRx to Boost Care and Access
VoxCell’s proprietary bioprinted tissues are designed to closely mimic the complexity of human tumors and other biological structures, providing drug developers with an advanced platform for evaluating efficacy, safety, and toxicity before conducting animal or human trials.
“Our mission has always been to make drug testing more human and meaningful,” said Karolina Valente, CEO of VoxCell BioInnovation. “Altasciences shares this forward-thinking approach, and we look forward to working together to help pharmaceutical and biotech companies make faster, more informed decisions.”
The collaboration will initially focus on drug screening for ophthalmic indications, with plans to expand to include other therapeutic areas and applications.
This partnership represents a shared vision: transforming early-stage research through innovation, integration, and smarter science for better outcomes for patients worldwide.
Source: Businesswire